Skip to main content
Premium Trial:

Request an Annual Quote

Kylin Receives Notice of Allowance for pRNA Patent

Premium

Kylin Therapeutics announced this week that it has been notified that the US Patent and Trademark Office will issue a patent broadly covering the company's core packaging RNA technology.

According to Kylin, pRNA is derived from bacteriophage phi29. The company characterizes it as a “gear in the DNA packaging machinery” that can be modified with therapeutic RNA such as siRNA.

The patent, the company said, "broadly covers a number of functionalities for … pRNA," including receptor binding, ribozyme activity and RNA interference. The intellectual property was exclusively licensed to Kylin by Purdue University.

Additional details about the IP were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.